FrancophonIA/ELRC3.0 huggingface dataset:
English: Dogs may lack energy, show lack of muscle coordination, vomit, have a loss of appetite, diarrhoea, salivate, have blood sugar levels higher than normal, be more sensitive to stimulation, and have a slow heartbeat or slow breathing.
Maltese: Il-klieb jista' jkollhom nuqqas ta' enerġija, juru nuqqas ta' koordinazzjoni filmuskoli, jirremettu, ikollhom nuqqas ta' aptit, dijarrea, salivazzjoni, ikollhom livelli ta' zokkor fiddemm li jkunu ogħla min-normal, ikunu aktar sensittivi għal stimulazzjoni, u jkollhom tnaqqis fit-taħbit tal-qalb jew teħid bil-mod tan-nifs.
English: Certifect is a medicine that contains three active substances, fipronil, (S)-methoprene and amitraz.
Maltese: Certifect huwa mediċina li fiha tliet sustanzi attivi, fipronil, (S)-methoprene u amitraz.
English: In the main field study, dogs of various breeds, age groups, gender and different weights were treated with either Certifect or a similar ‘spot-on' medicine containing fipronil and (S)-methoprene.
Maltese: Fl-istudju ewlieni fuq il-post, klieb ta' razez, gruppi ta' età, sess diversi u piżijiet differenti rċevew kura jew b'Certifect jew mediċina simili ‘lokalizzata' li kien fiha fipronil u (S)methoprene.
English: The medicine can be used in the management of flea allergy dermatitis (an allergic reaction to flea bites).
Maltese: Il-mediċina tista' tintuża fil-ġestjoni ta' dermatite allerġika għall-briegħed (reazzjoni allerġika għall-gdim tal-briegħed).
English: The active substances in Certifect act as ‘ectoparasiticides'.
Maltese: Is-sustanzi attivi f'Certifect jaġixxu bħala ‘ektoparasitiċidi'.
English: If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Maltese: Jekk tixtieq iktar informazzjoni abbażi tar-rakkomandazzjonijiet tasCVMP, aqra d-diskussjoni xjentifika (parti wkoll mill-EPAR).
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Certifect outweigh the risks for the approved indications and recommended that Certifect be given a marketing authorisation.
Maltese: ll-Kumitat għall-Prodotti Mediċinali għall-Użu Veterinarju (CVMP) ikkonkluda li l-benefiċċji ta' Certifect huma akbar mir-riskji tiegħu għall-indikazzjonijiet approvati, u rrakkomanda li Certifect jingħata awtorizzazzjoni għat-tqegħid fis-suq.
English: What is Certifect?
Maltese: Kif jaħdem Certifect?
English: How has Certifect been studied?
Maltese: Kif ġie studjat Certifect?
English: (S)Methoprene is absorbed into flea eggs or larvae, where it stops their development.
Maltese: (S)-Methoprene jiġi assorbit fil-bajd jew fil-larva talbriegħed, u jwaqqaf l-iżvilupp tagħhom.
English: Amitraz stimulates the nervous system of ticks, leading to hyperactivity and death of the ticks.
Maltese: Amitraz jistimula s-sistema nervuża tal-qurdien, li jwassal għal iperattività u l-mewt tal-qurdien.
English: Both fipronil and amitraz kill adult parasites while (S)-methoprene kills parasites at the egg or larval stage.
Maltese: Kemm fipronil kif ukoll amitraz joqtlu parassiti adulti filwaqt li (S)-methoprene joqtol parassiti fl-istadju tal-bajd jew tal-larva.
English: What is the risk associated with Certifect?
Maltese: X'inhu r-riskju assoċjat ma' Certifect?
English: Fipronil works on channels in the cells of the nervous system of ticks and fleas, blocking the transfer of ions in and out of cells,
Maltese: Fipronil jaħdem fuq kanali fiċ-ċelloli tas-sistema nervuża tal-qurdien u l-briegħed, billi jimblokka t-trasferiment ta' jonji 'l ġewwa u 'l barra miċ-ċelloli, li dan iwassal għal attività mhux ikkontrollata tas-sistema nervuża ċentrali u l-mewt ta' dawn il-parassiti.
English: Other studies were performed to investigate if Certifect reduced the risk of transmission of certain tick-borne diseases.
Maltese: Saru studji oħra biex jinvestigaw jekk Certifect naqqasx ir-riskju ta' trażmissjoni ta' ċertu mard li jinġarr mill-qurdien.
English: The content of one full Certifect pipette (appropriate to the dog's weight) is applied directly to the dog's skin, after parting its fur, in two separate spots (halfway down the back of the neck, and at the base of the neck).
Maltese: Il-kontenut ta' pipetta sħiħa ta' Certifect (addattat skont il-piż tal-kelb) jiġi applikat direttament lillġilda tal-kelb, wara li tifred il-pil tiegħu, f'żewġ postijiet separati (f'nofs il-parti t'isfel tal-għonq, u filbażi tal-għonq).
English: Certifect should not be allowed to enter surface water, as it may be harmful for aquatic organisms.
Maltese: Certifect ma għandux jitħalla jidħol fl-ilma tal-wiċċ, minħabba li jista' jkun ta' ħsara għall-organiżmi akwatiċi.
English: For a full list of all side effects reported with Certifect, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji kollha rrappurtati b'Certifect, ara l-fuljett ta' tagħrif.
English: The effectiveness of Certifect against ticks and fleas was investigated in both laboratory and field studies.
Maltese: L-effikaċja ta' Certifect kontra l-qurdien u l-briegħed kienet investigata kemm fi studji fil-laboratorju kif ukoll fi studji fuq il-post.
English: How does Certifect work?
Maltese: Għal xiex jintuża Certifect?
English: In addition, it has been shown that ticks detach more quickly from treated dogs, which indirectly reduces the risk of transmission of certain tickborne diseases to dogs from infected ticks.
Maltese: Barra minn hekk, intwera li l-qurdien jinqalgħu aktar malajr minn fuq klieb li kienu rċevew kura, li dan indirettament inaqqas ir-riskju ta' trażmissjoni ta' ċertu mard li jinġarr mill-qurdien għal fuq il-klieb minn qurdien infettat.
English: The studies showed that the effect of Certifect is comparable to that of the combination of fipronil with (S)-methoprene in reducing tick and flea counts in dogs.
Maltese: L-istudji wrew li l-effett ta' Certifect huwa komparabbli ma' dak tal-kombinazzjoni ta' fipronil ma' (S)methoprene fit-tnaqqis tal-għadd ta' qurdien u briegħed fil-klieb.
English: Dogs may show some temporary reactions at the site of application (skin discolouration, hair loss, itching or redness).
Maltese: Il-klieb jistgħu juru xi reazzjonijiet temporanji fis-sit tal-applikazzjoni (tibdil fil-kulur tal-ġilda, telf taxxagħar, ħakk jew ħmura).
English: Adjuvant MF59C.1 containing: squalene
Maltese: L-adjuvant MF59C.1 fih: Squalene polysorbate 80
English: (Invented) name
Maltese: Numru ta' l-EU Isem
English: Influenza virus surface antigens*, inactivated: A/Vietnam/1194/2004 (H5N1) - like strain used (NIBRG-14) 7.5 micrograms** per 0.5 ml dose * propagated in eggs ** expressed in microgram haemagglutinin.
Maltese: (H5N1) - razza simili użata (NIBRG-14) 7.5 mikrogrammi** għal kull doża ta'
English: Packaging Content (concentration) Package size
Maltese: Kontenut Daqs tal-pakkett
English: 9.75 milligrams polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams l t o r
Maltese: 7.5 mikrogrammi** għal kull doża ta' 0.5 ml
English: 10 pre-filled syringes
Maltese: 10 siringi mimlijin għallest
English: The full EPAR for Victrelis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The active substance in Victrelis, boceprevir, is a protease inhibitor.
Maltese: Is-sustanza attiva f'Victrelis, il-boceprevir, hija inibitur tal-proteażi.
English: Why has Victrelis been approved?
Maltese: Għaliex ġie approvat Victrelis?
English: In the study of previously untreated patients, 66% of patients who received Victrelis for 44 weeks (242 out 366) were cured compared with 38% of those who received placebo (137 out of 363).
Maltese: Fl-istudju fuq pazjenti li ma kinux irċevew kura preċedenti, 66% tal-pazjenti li rċevew Victrelis għal 44 ġimgħa (242 minn 366) kienu fiequ meta mqabbla ma' 38% ta' dawk li kienu rċevew plaċebo (137 minn 363).
English: Victrelis is a medicine that contains the active substance boceprevir.
Maltese: Victrelis huwa mediċina li fih is-sustanza attiva boceprevir.
English: This is a summary of the European public assessment report (EPAR) for Victrelis.
Maltese: Dan id-dokument huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Victrelis.
English: In a second study in patients in whom previous treatment had failed, the cure rate was 67% (107 out of 161) for patients who received Victrelis for 44 weeks compared with 21% (17 out of 80) for those
Maltese: Fit-tieni studju fuq pazjenti li kienu ħadu kura preċedenti iżda li din ma kinitx irnexxiet, ir-rata ta' kura kienet ta' 67% (107 minn 161) għall-pazjenti li rċevew Victrelis għal 44 ġimgħa meta mqabbla ma' 21% (17 minn 80) ta' dawk li rċevew plaċebo.
English: It blocks an enzyme called HCV NS3 protease, which is found on the hepatitis C virus of the type 1 genotype and is involved in the virus's replication.
Maltese: Din timblokka enżima tal-proteażi msejħa HCV NS3, li tinstab fuq il-virus tal-epatite Ċ tat-tip ġenotip 1 u hija involuta fir-replikazzjoni tal-virus.
English: In both studies Victrelis was compared with placebo (a dummy treatment).
Maltese: Fiż-żewġ studji Victrelis tqabbel ma' plaċebo (trattament finta).
English: What is the risk associated with Victrelis?
Maltese: Kif jaħdem Victrelis?
English: Two main studies involving 1,099 previously untreated and 404 previously treated patients with chronic hepatitis C genotype 1 infection and compensated liver disease were carried out.
Maltese: Saru żewġ studji ewlenin li fihom ħadu sehem 1,099 pazjent bl-infezzjoni tal-epatite Ċ kronika talġenotip 1 u b'mard tal-fwied ikkumpensat li ma kinux irċevew kura preċedenti u 404 pazjenti li kienu rċevew kura preċedenti.
English: Victrelis is used to treat adults with chronic (long-term) hepatitis C genotype 1 (a disease of the liver due to infection with the hepatitis C virus) in combination with two other medicines, peginterferon alfa
Maltese: Victrelis jintuża fil-kura ta' adulti bl-epatite Ċ kronika (fit-tul) tal-ġenotip 1 (marda tal-fwied minħabba infezzjoni bil-virus tal-epatite Ċ) f'kombinazzjoni ma' żewġ mediċini oħra, peginterferon alfa u ribavirin.
English: The company that makes Victrelis will ensure that all doctors expected to prescribe the medicine are provided with an educational pack with detailed information on the medicine, including information on the risk of anaemia and other side effects.
Maltese: Il-kumpanija li tagħmel Victrelis għandha tiżgura li t-tobba kollha li huma mistennija li jippreskrivu lmediċina jiġu pprovduti b'pakkett edukattiv li jkun fih informazzjoni dettaljata dwar il-mediċina, inkluż informazzjoni dwar ir-riskju tal-anemija u l-effetti sekondarji oħra.
English: All patients also received peginterferon alfa and ribavirin.
Maltese: Il-pazjenti kollha kienu wkoll irċevew il-peginterferon alfa u r-ribavirin.
English: The other most common side effects with Victrelis are fatigue (tiredness), nausea (feeling sick), headache and dysgeusia (taste disturbances).
Maltese: L-aktar effetti sekondarji komuni oħra b'Victrelis huma għejja, nawżja (tħossok ma tiflaħx), uġigħ ta' ras u disgewżja (disturbi fit-togħma).
English: Victrelis in combination with peginterferon alfa and ribavirin can lead to a higher rate of anaemia (low red blood cell counts) than is seen in treatment with peginterferon and ribavirin alone.
Maltese: Victrelis flimkien mal-peginterferon alfa and r-ribavirin jista' jwassal għal rata ogħla ta' anemija (għadd baxx taċ-ċelloli tad-demm ħomor) minn dik li tidher waqt kura bil-peginterferon u r-ribavirin weħidhom.
English: The CHMP noted that Victrelis in combination with peginterferon alfa and ribavirin significantly increases the number of patients cured of chronic hepatitis C infection.
Maltese: Is-CHMP innota li f'kombinazzjoni ma' peginterferon alfa u ribavirin, Victrelis iżid b'mod sinifikanti nnumru ta' pazjenti li fiequ mill-infezzjoni tal-epatite Ċ kronika.
English: What measures are being taken to ensure the safe use of Victrelis?
Maltese: X'miżuri qegħdin jittieħdu biex jiġi assigurat l-użu bla periklu ta' Victrelis?
English: These medicines can be harmful at high levels in the blood and it is important to avoid taking them when taking Victrelis.
Maltese: Dawn il-mediċini jistgħu jkunu ta' ħsara f'livelli għoljin fid-demm u huwa importanti li tevita milli teħodhom waqt li tkun qed tieħu Victrelis.
English: The recommended dose is four capsules three times a day (a total of 12 capsules a day).
Maltese: Jiġi bħala kapsuli (200 mg).
English: Victrelis was effective at curing patients with chronic hepatitis C genotype 1 infection who were also treated with peginterferon alfa and ribavirin.
Maltese: Victrelis kien effettiv fil-kura ta' pazjenti bl-infezzjoni tal-epatite Ċ kronika tal-ġenotip 1 li kienu wkoll irċevew kura bil-peginterferon alfa u r-ribavirin.
English: When the enzyme is blocked, the virus does not replicate normally and this slows down the rate of replication, helping to eliminate the virus.
Maltese: Meta l-enżima tiġi mblukkata, il-virus ma jirreplikax b'mod normali u dan inaqqas ir-rata ta' replikazzjoni, u jgħin biex il-virus jiġi eliminat.
English: For more information on how to use Victrelis, including its combination with peginterferon alfa and ribavirin and the length of treatment, see the summary of product characteristics (also part of the EPAR).
Maltese: Għal aktar informazzjoni dwar kif għandek tuża Victrelis, inkluż il-kombinazzjoni tiegħu ma' peginterferon alfa u ribavirin u t-tul tal-kura, ara ssommarju tal-karatteristiċi tal-prodott (ukoll parti mill-EPAR).
English: This was an important improvement on results seen with only peginterferon alfa and ribavirin together.
Maltese: Dan kien titjib importanti fuq ir-riżultati li kienu dehru bil-kombinazzjoni tal-peginterferon alfa u r-ribavirin biss.
English: Victrelis can slow down the rate at which certain medicines are broken down in the liver.
Maltese: Victrelis jista' jnaqqas ir-rata li biha ċerti mediċini jitkissru fil-fwied.
English: All MAHs should have in place a Risk management plan (RMP).
Maltese: L-MAHs kollha għandu jkollhom fis-seħħ Pjan ta' ġestjoni tar-riskji (RMP).
English: The MAHs of medicinal products with substances related to valproate shall conduct a retrospective observational study to investigate the association between paternal exposure to valproate and the risk of congenital anomalies and neurodevelopmental disorders including autism in offspring.
Maltese: L-MAHs ta' prodotti mediċinali b'sustanzi relatati ma' valproate għandhom iwettqu studju ta' osservazzjoni retrospettiv sabiex jinvestigaw l-assoċjazzjoni bejn l-esponiment paternali għal valproate u r-riskju ta' anomaliji konġenitali u d-disturbi li jirrigwardaw l-iżvilupp newroloġiku inkluż l-awtiżmu fil-wild.
English: The MAHs of medicinal products with substances related to valproate shall conduct a PASS preferably based on existing registries to further characterise the foetal anticonvulsant syndrome in children with valproate in utero exposure as compared to other anti-epileptic drugs.
Maltese: L-MAHs ta' prodotti mediċinali b'sustanzi relatati ma' valproate għandhom iwettqu PASS preferibbilment ibbażat fuq ir-reġistri eżistenti sabiex jiġi kkaratterizzat aktar is-sindrome antikonvulsiv fetali fit-tfal b'esponiment in utero għal valproate meta mqabbel ma' prodotti antiepilettiċi oħrajn.
English: The MAHs of medicinal products with substances related to valproate shall perform a survey among HCP to assess knowledge of HCP and behaviour with regard to PPP as well as receipt/use of DHPC and educational materials.
Maltese: L-MAHs ta' prodotti mediċinali b'sustanzi relatati ma' valproate għandhom iwettqu stħarriġ fost l-HCP sabiex jivvalutaw l-għarfien tal-HCP u l-imġiba fir-rigward tal-PPP kif ukoll il-wasla/l-użu tadDHPC u materjali edukattivi.
English: The MAHs of medicinal products with substances related to valproate shall develop and submit educational materials according to agreed core elements.
Maltese: L-MAHs ta' prodotti mediċinali b'sustanzi relatati ma' valproate għandhom jiżviluppaw u jippreżentaw materjali edukattivi skont lelementi ewlenin maqbula.
English: The marketing authorisation holders shall complete the below conditions, within the stated timeframe, and competent authorities shall ensure that the following is fulfilled:
Maltese: Dawn għandhom jiġu ppreżentati lill-Awtoritajiet Nazzjonali Kompetenti:
English: The MAHs of medicinal products with substances related to valproate shall conduct an observational study to evaluate and identify the best practices for switching of valproate in clinical practice.
Maltese: L-MAHs ta' prodotti mediċinali b'sustanzi relatati ma' valproate għandhom iwettqu studju ta' osservazzjoni sabiex jevalwaw u jidentifikaw l-aħjar prattiki għall-bidla ta' valproate fl-prattika klinika.
English: 125 doses
Maltese: 125 doża
English: 10 x 25 doses 10 x 50 doses 4 x 125 doses
Maltese: 10 x 25 doża 10 x 50 doża 4 x 125 doża
English: EU/2/15/190/001 EU/2/15/190/002 EU/2/15/190/003 EU/2/15/190/004 EU/2/15/190/005 EU/2/15/190/006
Maltese: EU/2/15/190/001 EU/2/15/190/002 EU/2/15/190/003 EU/2/15/190/004
English: Date of first authorization: 06/11/2015.
Maltese: DATA TAL-EWWEL AWTORIZZAZZJONI / TIĠDID TAL-AWTORIZZAZZJONI Data tal-ewwel awtorizzazzjoni: 06/11/2015.
English: Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIUM
Maltese: Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Maltese: * Il-frekwenza ta' effetti mhux mixtieqa hija definita skont din il-konvenzjoni: - komuni ħafna (aktar minn wieħed f'10 annimali li juru effetti mhux mixtieqa matul il-perjodu ta' kura waħda) - komuni (aktar minn wieħed iżda inqas minn 10 annimali f'100 annimal) - mhux komuni (aktar minn wieħed iżda inqas minn10 annimali f'1,000 annimal) - rari (aktar minn wieħed iżda inqas minn10 annimali f'10,000 annimal) - rari ħafna (inqas minn annimal wieħed f'10,000 annimal, inklużi rapporti iżolati).
English: 25 doses 50 doses 125 doses
Maltese: 25 doża 50 doża 125 doża
English: 0.2 mg *Relative potency unit determined by ELISA antigen quantification (in vitro potency test) compared to a reference vaccine.
Maltese: 0.2 mg * Unità ta' qawwa relattiva determinata mill-ammont ta' antiġeni bl-ELISA (test ta' qawwa in vitro)
English: Inactivated Mycoplasma hyopneumoniae, strain P-5722-3
Maltese: Mycoplasma hyopneumoniae, strejn P-5722-3 inattivat
English: It is intended to stimulate active immunity against PCV2 and Mycoplasma hyopneumoniae in pigs.
Maltese: Huwa intenzjonat biex jistimola immunità attiva kontra PCV2 u Mycoplasma hyopneumoniae fil-ħnieżer.
English: Zoetis WHC 2 LLC 2000 Rockford Road, Charles City IA 50616 USA
Maltese: Rockford Road, Charles City
English: The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009.
Maltese: Is-sustanza attiva billi hi ta' prinċipju t'oriġini bijoloġika intenzjonata biex tipproduċi immunità attiva ma taqax fl-iskop tar-Regolament tal-Kummissjoni (UE) Nru 470/2009.
English: Pharmacotherapeutic group: immunologicals for Suidae, inactivated viral and inactivated bacterial vaccines for pigs.
Maltese: Grupp farmako-terapewtiku: immunoloġiċi għas-Suidae, vaċċini virali inattivati u batteriċi inattivati għal ħnieżer.
English: The vaccine also contains inactivated Mycoplasma hyopneumoniae.
Maltese: Il-vaċċin fih ukoll Mycoplasma hyopneumoniae inattivat.
English: Inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 ORF2 protein Inactivated Mycoplasma hyopneumoniae strain P-5722-3
Maltese: Rikombinant kimeriku tal-porcine circovirus tip 1 inattivat li fih il proteina ORF2 tal-porcine circovirus tip 2 Mycoplasma hyopneumoniae, strejn P-5722-3 inattivat
English: Each dose (2 ml) contains:
Maltese: Kull doża (2 ml) fiha:
English: Lot: {number}
Maltese: JISK {xahar/sena}
English: Thiomersal Squalane Poloxamer 401 Polysorbate 80 Monobasic potassium phosphate anhydrous Sodium chloride Potassium chloride Disodium phosphate anhydrous Sodium phosphate dibasic heptahydrate Disodium tetraborate decahydrate EDTA tetrasodium Water for injections
Maltese: Disodium phosphate anhydrous Disodium tetraborate decahydrate EDTA tetrasodium
English: Suvaxyn Circo+MH RTU emulsion for injection for pigs
Maltese: VETERINARJU Suvaxyn Circo+MH RTU emulsjoni għal injezzjoni fil-ħnieżer.
English: Cardboard box of 10 vials of 50 ml (25 doses) or 100 ml (50 doses).
Maltese: Kaxxa tal-kartun b'10 kunjetti ta' 50 ml (25 doża) jew 100 ml (50 doża).
English: The area of local tissue reactions is in general below 2 cm in diameter.
Maltese: B'mod ġenerali il-firxa tar-reazzjonijiet lokali tattessuti hija anqas minn 2 cm fid-dijametru.
English: Cardboard box of 4 vials of 250 ml (125 doses).
Maltese: Kaxxa tal-kartun b'4 kunjetti ta' 250 ml (125 doża).
English: 25 doses 50 doses
Maltese: 50 doża
English: The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Maltese: L-addittivi elenkati f‘sezzjoni 6.1 tal-Karatteristiċi tal-Prodott fil-Qosor huma sustanzi ammissibbli li għalihom m'hemmx bżonn ta' limiti massimi ta' residwi kif indikat fit-tabella numru 1 tal-anness tarRegolament tal-Kummissjoni (UE) Nru 37/2010 jew huma kkunsidrati li ma jaqgħux fi ħdan l-iskop tar-Regolament (KE) Nru 470/2009 meta użati bħal f'dan il-prodott mediċinali veterinarju.
English: Pigs (for fattening)
Maltese: kura waħda)
English: ATCvet code: QI09AL
Maltese: TAL-PRODOTT FIL-QOSOR
English: A transient increase in body temperature (on average 0.8°C) was observed 4 hours after administration of a 2-fold overdose.
Maltese: Żieda li tgħaddi fit-temperatura tal-ġisem (medja ta 0.8°C) ġiet osservata 4 sigħat wara lamministrazzjoni ta' doża eċċessiva b'darbtejn.
English: Inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 ORF2 protein
Maltese: Il-vaċċin fih rikombinant kimeriku tal-porcine circovirus tip 1 inattivat li fih il-proteina ORF2 talporcine circovirus tip 2.
English: For active immunization of pigs from 3 weeks of age against Mycoplasma hyopneumoniae to reduce lung lesions caused by infection with M. hyopneumoniae.
Maltese: Għal tilqim attiv ta' ħnieżer minn età ta' 3 ġimgħat kontra Mycoplasma hyopneumoniae biex inaqqas il-leżjonijiet fil-pulmun ikkawżati minn infezzjoni b'M. hyopneumoniae.
English: The vaccine contains an inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 ORF2 protein.
Maltese: QI09AL Il-vaċċin fih rikombinant kimeriku tal-porcine circovirus tip 1 inattivat li fih il-proteina ORF2 tal porcine circovirus tip 2.
English: For active immunization of pigs from the age of 3 weeks against Mycoplasma hyopneumoniae to reduce lung lesions caused by infection with M. hyopneumoniae.
Maltese: Għal tilqim attiv ta' ħnieżer minn età ta' 3 ġimgħat kontra Mycoplasma hyopneumoniae biex inaqqas il-leżjonijiet fil-pulmun ikkawżati minn infezzjoni b' M. hyopneumoniae.
English: Duration of immunity: 23 weeks after vaccination
Maltese: Tul tal-immunità: 23 ġimgħa wara t-tilqima
English: In individual pigs the temperature increase compared to pre-treatment may commonly exceed 2°C.
Maltese: Huwa komuni li fi ħnieżer individwali t-temperatura taqbeż iż-2°C meta mqabbla ma' dik ta' qabel it-trattament.
English: Macrogol (400) Iron oxide yellow (E172)
Maltese: Iron oxide yellow (E172)